A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dato-DXd

Sponsor

AstraZeneca

Collaborators

[object Object]